首页 | 本学科首页   官方微博 | 高级检索  
检索        

Review of the Regulations for Clinical Research in Herbal Medicines in USA
作者姓名:Tony Yuqi Tang  LI Fang-zhou  Janyne Afseth
作者单位:Herose Clinical Centre,190 Clemenceau Ave,;Department of Law,School of Humanities,Inner Mongolia University of Technology;School of Nursing,Midwifery & Social Care,Faculty of Health,Life & Social Sciences,Edinburgh Napier University,Sighthill Campus Sighthill Court,Edinburgh EH114BN,UK
摘    要:In 2012,USA Food and Drug Administration(FDA) approved 39 new drugs,however,there are only two botanical drugs(one topical and one oral)approved by FDA since the publication of the FDA's industry guidelines for the botanical drug product in June 2004.The approval shows the Western guideline can be used for herbal medicines,authors investigate current regulation on herbal medicine clinical research,identify challenges conducting clinical trials,and seek to produce some guidance for potential investigators and sponsors considering a clinical trial in this area.Key words were formulated for searching on Medline and FDA website to locate relevant regulations for clinical research in herbal medicines to understand current environment for herbal medicine usage and examine the barriers affecting herbal medicine in clinical trials.Authors critically explore case study of the 1st FDA approved botanical drugs,Veregen(sinecatechins),green tea leaves extract,a topical cream for perianal and genital condyloma.In consideration of current regulation environment in USA,based on the findings and analysis through the literature review and Veregen case study,authors produce and propose a Checklist for New Drug Application of Herbal Medicines for potential investigators and sponsors considerina in a herbal medicine clinical trial.

关 键 词:临床试验  美国食品  中草药  Medline  规例  中药新药  FDA  茶叶提取物

Review of the Regulations for Clinical Research in Herbal Medicines in USA
Authors:Tony Yuqi Tang and LI Fang-zhou  Janyne Afseth
Abstract:In 2012,USA Food and Drug Administration(FDA) approved 39 new drugs,however,there are only two botanical drugs(one topical and one oral)approved by FDA since the publication of the FDA's industry guidelines for the botanical drug product in June 2004.The approval shows the Western guideline can be used for herbal medicines,authors investigate current regulation on herbal medicine clinical research,identify challenges conducting clinical trials,and seek to produce some guidance for potential investigators and sponsors considering a clinical trial in this area.Key words were formulated for searching on Medline and FDA website to locate relevant regulations for clinical research in herbal medicines to understand current environment for herbal medicine usage and examine the barriers affecting herbal medicine in clinical trials.Authors critically explore case study of the 1st FDA approved botanical drugs,Veregen(sinecatechins),green tea leaves extract,a topical cream for perianal and genital condyloma.In consideration of current regulation environment in USA,based on the findings and analysis through the literature review and Veregen case study,authors produce and propose a Checklist for New Drug Application of Herbal Medicines for potential investigators and sponsors considerina in a herbal medicine clinical trial.
Keywords:herbal medicine  Chinese medicine  clinical trial  traditional medicine  complementary medicine  review
本文献已被 CNKI 维普 等数据库收录!
点击此处可从《Chinese Journal of Integrated Traditional and Western Medicine》浏览原始摘要信息
点击此处可从《Chinese Journal of Integrated Traditional and Western Medicine》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号